EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MFAP2 promotes HSCs activation through FBN1 / TGF ‐β/Smad3 pathway

Yonghong Sun, Xingxing Chen, Lili Chen, Baixin Bao, Chunming Li, Yongning Zhou iD

Journal of Cellular and Molecular Medicine · 2023

DOI: 10.1111/jcmm.17884 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2023. Verfasst von Yonghong Sun und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, China. Hauptthemen laut MEDLINE: Microfibrils, Transforming Growth Factor beta. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liver fibrosis is a chronic inflammatory process characterized by the accumulation of extracellular matrix (ECM), which contributes to cirrhosis and hepatocellular carcinoma. Increasing evidence suggests that the activation of hepatic stellate cells (HSCs) under an inflammatory state leads to the secretion of collagens, which can cause cirrhosis. In this study, we analysed data from the Gene Expression Omnibus (GEO) databases to identify differentially expressed genes (DEGs) between quiescent and fibrotic HSCs. We found that Microfibril Associated Protein 2 (MFAP2) was elevated in carbon tetrachloride (CCl4)‐induced liver fibrosis and Transforming Growth Factor‐Beta 1 (TGF‐β1)‐activated HSCs. Knockdown of MFAP2 inhibited HSC proliferation and partially attenuated TGF‐β‐stimulated fibrogenesis markers. Bioinformatics analysis revealed that Fibrillin‐1 (FBN1) was correlated with MFAP2, and the expression of FBN1 was significantly upregulated after MFAP2 overexpression. Silencing MFAP2 partially attenuated the activation of HSCs by inhibiting HSC proliferation and decreasing collagen deposits. In vitro results showed that the inhibition of MFAP2 alleviated hepatic fibrosis by inhibiting the activation and inducing the apoptosis of active HSCs in a CCl4‐induced mouse model. In conclusion, our results suggest that MFAP2 is a potential target for the clinical treatment of liver fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicrofibrilsTransforming Growth Factor betaAnimalsMiceCarbon TetrachlorideFibrillin-1Hepatic Stellate CellsLiverLiver CirrhosisTransforming Growth Factor beta1RNA Splicing Factors

Stichwörter der Autor:innen

FBN1HSCsMFAP2TGF-β1liver fibrosis

Substanzen

Carbon TetrachlorideFibrillin-1Transforming Growth Factor betaTransforming Growth Factor beta1microfibrillar proteinRNA Splicing Factors

Autor:innen und Institutionen

  • Department of Gastroenterology, The First Hospital of Lanzhou University, Lanzhou, China.
  • Department of Pediatrics, Gansu Province People's Hospital, Lanzhou, People's Republic of China.
  • The First School of Clinical Medicine, Gansu University of Chinese Medicine, Lanzhou, People's Republic of China.
  • Department of Obstetrics, Gansu Province People's Hospital, Lanzhou, People's Republic of China.

ORCID-Profile: Yongning Zhou

Zitieren

APA

Sun, Y., Chen, X., Chen, L., Bao, B., Li, C., & Zhou, Y. (2023). MFAP2 promotes HSCs activation through FBN1 / TGF ‐β/Smad3 pathway. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.17884

Vancouver

Sun Y, Chen X, Chen L, Bao B, Li C, Zhou Y. MFAP2 promotes HSCs activation through FBN1 / TGF ‐β/Smad3 pathway. Journal of Cellular and Molecular Medicine. 2023. doi:10.1111/jcmm.17884

BibTeX
@article{Sun2023,
  author = {Sun, Yonghong and Chen, Xingxing and Chen, Lili and Bao, Baixin and Li, Chunming and Zhou, Yongning},
  title = {MFAP2 promotes HSCs activation through FBN1 / TGF ‐β/Smad3 pathway},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2023},
  doi = {10.1111/jcmm.17884}
}
Kostenlos starten →